These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 18661358)

  • 1. Targeted therapy--possible new therapeutic option for malignant mesothelioma?
    Dobra K; Hjerpe A
    Connect Tissue Res; 2008; 49(3):270-2. PubMed ID: 18661358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYC-induced sensitivity of human malignant melanoma to proteasome inhibitors - a KaMYCaze effect.
    Fuchs SY
    Pigment Cell Melanoma Res; 2008 Feb; 21(1):9-10. PubMed ID: 18353138
    [No Abstract]   [Full Text] [Related]  

  • 3. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
    Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
    Cvek B; Dvorak Z
    Drug Discov Today; 2008 Aug; 13(15-16):716-22. PubMed ID: 18579431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of the proteasome in leukaemia.
    McCloskey SM; McMullin MF; Walker B; Irvine AE
    Hematol Oncol; 2008 Jun; 26(2):73-81. PubMed ID: 18324639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The persisting challenge of selective and specific proteasome inhibition.
    Groll M; Huber R; Moroder L
    J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress.
    Nilsonne G; Sun X; Nyström C; Rundlöf AK; Potamitou Fernandes A; Björnstedt M; Dobra K
    Free Radic Biol Med; 2006 Sep; 41(6):874-85. PubMed ID: 16934670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focusing on boron in medicinal chemistry.
    Ramachandran PV
    Future Med Chem; 2013 Apr; 5(6):611-2. PubMed ID: 23617421
    [No Abstract]   [Full Text] [Related]  

  • 9. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
    Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible mechanism(s) of action of bortezomib in a patient with bronchioloalveolar carcinoma.
    Garfield DH; Cadranel JL
    Lung Cancer; 2007 Aug; 57(2):249-50. PubMed ID: 17599646
    [No Abstract]   [Full Text] [Related]  

  • 11. BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis.
    Liu P; Xu B; Li J; Lu H
    FEBS Lett; 2009 Jan; 583(2):401-6. PubMed ID: 19111544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of bortezomib-induced apoptosis by red blood cell uptake.
    Wheat LM; Kohlhaas SL; Monbaliu J; De Coster R; Majid A; Walewska RJ; Dyer MJ
    Leukemia; 2006 Sep; 20(9):1646-9. PubMed ID: 16791268
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytotoxic activities of nucleoside and nucleobase analog drugs in malignant mesothelioma: characterization of a novel nucleobase transport activity.
    Damaraju D; Damaraju VL; Brun M; Mowles D; Kuzma M; Berendt RC; Sawyer MB; Cass CE
    Biochem Pharmacol; 2008 May; 75(10):1901-11. PubMed ID: 18371936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.
    Labussiere M; Pinel S; Delfortrie S; Plenat F; Chastagner P
    Oncol Rep; 2008 Nov; 20(5):1283-7. PubMed ID: 18949434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
    Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
    Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition: a new therapeutic option in lupus nephritis?
    van der Vlag J; Berden JH
    Nephrol Dial Transplant; 2008 Dec; 23(12):3771-2. PubMed ID: 18809973
    [No Abstract]   [Full Text] [Related]  

  • 17. Malignant mesothelioma--a connective tissue tumor with proteoglycan-dependent differentiation.
    Hjerpe A; Dobra K
    Connect Tissue Res; 2008; 49(3):249-51. PubMed ID: 18661353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
    Mitsiades CS
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S23-7. PubMed ID: 19795532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
    Basler M; Lauer C; Beck U; Groettrup M
    J Immunol; 2009 Nov; 183(10):6145-50. PubMed ID: 19841190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Aghajanian C; Blessing JA; Darcy KM; Reid G; DeGeest K; Rubin SC; Mannel RS; Rotmensch J; Schilder RJ; Riordan W;
    Gynecol Oncol; 2009 Nov; 115(2):215-20. PubMed ID: 19712963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.